MC
ALNY icon

Mathes Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Mathes Company’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$348K Hold
1,155
– – 0.11% 97
2026
Q1 		$382K Hold
1,155
– – 0.14% 90
2025
Q4 		$459K Hold
1,155
– – 0.16% 85
2025
Q3 		$527K Hold
1,155
– – 0.19% 81
2025
Q2 		$377K Buy
+1,155
New +$320K 0.14% 97

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mathes Company's ALNY Position: Q2 2026 in Review

Mathes Company held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 1,155 shares worth $348K. The position accounts for 0.11% of the portfolio, ranked #97.

Mathes Company first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $527K in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Mathes Company held 1,155 shares of Alnylam Pharmaceuticals worth $348K as of Q2 2026.
  • Mathes Company left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.11% of Mathes Company's portfolio in Q2 2026, its #97 holding.
  • Mathes Company first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Mathes Company's Alnylam Pharmaceuticals position peaked at $527K in Q3 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Mathes Company's 13F filing for Q2 2026, filed 11 Aug 2026.